Brian R Wong, 52198 Garland Way, Los Altos, CA 94022

6492124, Dec 10, 2002

Jun 11, 1999

09/330867

Brian Wong - New York NY
Daniel Besser - New York NY
Yongwon Choi - New York NY

The Rockefeller University - New York NY

G01N 33567

435 71, 514 2, 530350

The present invention relates to methods and compositions for modulating activity of a TRANCE receptor, including the modulation of TRANCE signaling activity. In particular, the invention provides screening methods by which novel modulators of TRANCE signaling may be identified, including TRANCE inhibitors, agonists and antagonists. The invention also relates to the identification of one or more specific pathways for osteoclast surivival, and the manipulation of this pathway (e. g. , using a TRANCE modulator of the invention). Such manipulation may provide strategies for treating osteoclast-related diseases such as osteoporosis and osteopetrosis.

6880060, Apr 12, 2005

Apr 24, 2002

10/131912

Nisha D. Talagala - Fremont CA, US
Brian Wong - Gordonsville VA, US

Sun Microsystems, Inc. - Palo Alto CA

G06F012/00

711170, 711171, 711172, 711173, 711202, 711206, 711209, 714 8, 714 52

A method for embedding integrity metadata. In one exemplary embodiment, a plurality of integrity metadata segments is determined. Each integrity metadata segment is associated with a segment of user data. The user data is mapped to a plurality of physical sectors, each physical sector containing a segment of user data and the associated integrity metadata segment. For one exemplary embodiment, a common I/O data block size is determined, and its data is mapped into a number of 512-byte sectors. The number of 512-byte sectors corresponds to the number required for the common I/O data block size plus one or more additional 512-byte sectors. This creates additional space in each sector to accommodate the integrity metadata. Integrity metadata for each data segment of the common I/O size is determined. The integrity metadata for each sector is mapped to the additional space of each sector.

6890725, May 10, 2005

Jul 23, 2002

10/202481

Marcy K. Vallone - San Francisco CA, US
Brian R. Wong - San Mateo CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US

Rigel Pharmaceuticals, Inc. - South San Francisco CA

C12Q001/42
G01N033/53

435 724, 435 721, 435 21

The present invention provides compositions and methods for modulating B-lymphocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating B-lymphocyte activation are provided. Compositions and methods for the treatment of disorders related to dysfunction or dysregulation of B-lymphocyte activation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating B-lymphocyte activation.

6929923, Aug 16, 2005

Jul 23, 2002

10/202480

Marcy K. Vallone - San Francisco CA, US
Brian R. Wong - Los Altos CA, US
Esteban Masuda - Menlo Park CA, US
Mark Powell - Burlingame CA, US

Rigel Pharmaceuticals, Inc. - South San Francisco CA

C12Q001/02

435 724, 435 29

The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.

7019119, Mar 28, 2006

Dec 14, 2001

10/017910

Yongwon Choi - New York NY, US
Brian Wong - New York NY, US
Regis Josien - New York NY, US
Ralph Steinman - Westport CT, US

The Rockefeller University - New York NY

C07K 16/24
C07K 16/46

5303881, 5303891, 5303873, 5303871, 53038823, 5303892, 5303913

A protein belonging to the TNF superfamily called TRANCE involved in signal transduction, along with nucleic acids comprising DNA sequences and degenerate variants thereof which encode TRANCE are disclosed. Modulators which are TRANCE agonists and TRANCE antagonists are also disclosed, and can be used in pharmaceutical compositions and methods disclosed herein to modulate the active life of mature dendritic cells, T cell activation, and immune response in mammal.

7020805, Mar 28, 2006

Aug 15, 2002

10/222074

Nisha D. Talagala - Fremont CA, US
Brian Wong - Palo Alto CA, US

Sun Microsystems, Inc. - Palo Alto CA

G06F 11/00

714 42

A method for detecting a phantom write error in a data storage system is described. In one embodiment, upon receiving a read command pertaining to a data block stored on a storage medium, two version identifiers associated with the data block are compared. A first version identifier is stored within the data block and a second version identifier is stored outside of the data block. If the version identifiers do not match, the possible occurrence of a phantom write error is detected.

7045308, May 16, 2006

Mar 29, 2002

10/112674

Brian Wong - Los Altos CA, US
Chong Alan Fu - Sunnyvale CA, US
Helena Mancebo - Fremont CA, US
Xiulan X.Z. Zhou - Palo Alto CA, US

Rigel Pharmaceuticals, Inc. - South San Francisco CA

C12N 15/12
C12N 15/63
C12N 15/00
G01N 33/53

435 78, 435325, 4353201, 435 691

The present invention provides compositions and methods for modulating leukocyte activation. Nucleic acids encoding proteins and proteins so encoded which are capable of modulating leukocyte activation are provided. Compositions and methods for the treatment of disorders related to leukocyte dysfunction or dysregulation are also provided. Prophylactics and methods for the prevention of such disorders are also provided. Also provided are compositions and methods for diagnostic and prognostic determination of such disorders. Further provided are assays for the identification of bioactive agents capable of modulating leukocyte activation.

7051155, May 23, 2006

Aug 5, 2002

10/212861

Nisha Talagala - Fremont CA, US
Brian Wong - Gordonsville VA, US

Sun Microsystems, Inc. - Santa Clara CA

G06F 12/00

711114, 714 6

A data layout mechanism is described for allocating metadata within a storage system employing data striping. The data layout mechanism includes a number of storage devices, each of the storage devices having storage spaces allocated to store individual data stripe units associated with a number of stripes. The data layout mechanism further includes a plurality of metadata chunks allocated within the storage devices such that (1) metadata associated with at least two data stripe units of the same stripe is stored within a single metadata chunk, and (2) the metadata chunks are evenly distributed across the storage devices.